Alvotech (NASDAQ:ALVO) Shares Down 5.1% – Here’s Why

Alvotech (NASDAQ:ALVO) shares traded down 5.1% on Monday . The company traded as low as $3.33 and last traded at $3.35. 510,264 shares changed hands during trading, a decline of 3% from the average session volume of 527,896 shares. The stock had previously closed at $3.53.

Trending Headlines about Alvotech

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: UBS reiterated a Buy and cut its price target to $6, signaling continued analyst conviction in Alvotech’s long-term biosimilar potential despite the lower target. Article Title
• Positive Sentiment: Reported short interest declined to ~2.46M shares as of March 13 (down ~17% from Feb. 26), reducing one potential source of downward price pressure (short-interest ratio ~3.7 days; ~0.8% of shares sold short).
• Neutral Sentiment: Multiple recent short-interest reports contain inconsistent/zero figures (likely data errors). Investors should treat conflicting filings cautiously and watch the next official short-interest release for clarity.
• Negative Sentiment: Barclays cut its price target to $4 and moved to an Underweight rating, increasing sell-side downside pressure and signaling weaker near-term expectations for revenue/profitability. Article Title
• Negative Sentiment: Alvotech set a new 52-week low after the analyst downgrades, highlighting persistent negative sentiment and technical weakness that can amplify downward moves. Article Title

Analyst Upgrades and Downgrades

ALVO has been the subject of a number of research analyst reports. Barclays reduced their target price on Alvotech from $5.00 to $4.00 and set an “underweight” rating for the company in a research note on Tuesday. UBS Group cut their price objective on Alvotech from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Alvotech in a research note on Wednesday, January 21st. Morgan Stanley set a $10.00 target price on Alvotech in a report on Wednesday, December 3rd. Finally, Zacks Research upgraded Alvotech from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 19th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $7.60.

Alvotech Stock Up 0.3%

The company has a market capitalization of $946.65 million, a price-to-earnings ratio of 31.40 and a beta of 0.16. The business’s 50-day moving average is $4.46 and its 200-day moving average is $5.77.

Alvotech (NASDAQ:ALVO) last announced its quarterly earnings results on Wednesday, March 18th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.50). The company had revenue of $173.20 million for the quarter, compared to analyst estimates of $162.20 million. Alvotech had a negative return on equity of 12.84% and a net margin of 4.74%. As a group, analysts expect that Alvotech will post -0.07 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Alvotech by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock worth $35,481,000 after purchasing an additional 114,255 shares in the last quarter. Legal & General Group Plc grew its position in Alvotech by 17.0% during the second quarter. Legal & General Group Plc now owns 657,742 shares of the company’s stock valued at $6,028,000 after buying an additional 95,331 shares during the period. Millennium Management LLC grew its position in Alvotech by 1,707.7% during the fourth quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock valued at $1,832,000 after buying an additional 337,417 shares during the period. Goldman Sachs Group Inc. increased its holdings in Alvotech by 88.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock valued at $1,331,000 after buying an additional 122,089 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Alvotech by 10.7% in the fourth quarter. Geode Capital Management LLC now owns 254,921 shares of the company’s stock valued at $1,308,000 after buying an additional 24,667 shares in the last quarter.

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).